Zhexu Wen

614 total citations
16 papers, 400 citations indexed

About

Zhexu Wen is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Zhexu Wen has authored 16 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Oncology. Recurrent topics in Zhexu Wen's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Zhexu Wen is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (10 papers) and Radiomics and Machine Learning in Medical Imaging (5 papers). Zhexu Wen collaborates with scholars based in China and United States. Zhexu Wen's co-authors include Fangqiu Fu, Haiquan Chen, Yuan Li, Shengping Wang, Yang Zhang, Yue Zhao, Zhendong Gao, Xuxia Shen, Chaoqiang Deng and Hong Hu and has published in prestigious journals such as CHEST Journal, International Journal of Cancer and Frontiers in Immunology.

In The Last Decade

Zhexu Wen

16 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhexu Wen China 10 296 139 86 70 55 16 400
Kei Miyoshi Japan 10 259 0.9× 50 0.4× 130 1.5× 57 0.8× 24 0.4× 13 401
Shunki Hirayama Japan 6 205 0.7× 72 0.5× 149 1.7× 32 0.5× 27 0.5× 17 357
Shanbo Zheng China 12 350 1.2× 69 0.5× 201 2.3× 146 2.1× 119 2.2× 28 473
José Padilla Spain 7 387 1.3× 84 0.6× 220 2.6× 39 0.6× 28 0.5× 18 490
Naikang Zhou China 10 250 0.8× 48 0.3× 141 1.6× 84 1.2× 49 0.9× 40 401
Vérane Achard Switzerland 10 263 0.9× 54 0.4× 87 1.0× 79 1.1× 71 1.3× 37 359
Chang Hun Lee South Korea 11 230 0.8× 49 0.4× 128 1.5× 88 1.3× 73 1.3× 23 375
Emily S. Weg United States 6 204 0.7× 38 0.3× 82 1.0× 63 0.9× 107 1.9× 23 266
Beverly Schmocker Canada 6 134 0.5× 61 0.4× 78 0.9× 33 0.5× 31 0.6× 6 253
Riccardo Galassi Italy 8 166 0.6× 144 1.0× 101 1.2× 42 0.6× 19 0.3× 15 327

Countries citing papers authored by Zhexu Wen

Since Specialization
Citations

This map shows the geographic impact of Zhexu Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhexu Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhexu Wen more than expected).

Fields of papers citing papers by Zhexu Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhexu Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhexu Wen. The network helps show where Zhexu Wen may publish in the future.

Co-authorship network of co-authors of Zhexu Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Zhexu Wen. A scholar is included among the top collaborators of Zhexu Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhexu Wen. Zhexu Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Wen, Zhexu, Fangqiu Fu, Yue Zhao, et al.. (2023). Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer. Translational Lung Cancer Research. 12(11). 2157–2168. 2 indexed citations
2.
Chen, Shuilin, et al.. (2022). Characterization of immune microenvironment infiltration and m6A regulator-mediated RNA methylation modification patterns in osteoarthritis. Frontiers in Immunology. 13. 1018701–1018701. 4 indexed citations
3.
Deng, Chaoqiang, Yang Zhang, Fangqiu Fu, et al.. (2021). Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma. European Journal of Cardio-Thoracic Surgery. 60(5). 1223–1231. 10 indexed citations
4.
Fu, Fangqiu, Yang Zhang, Zhendong Gao, et al.. (2021). Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 147(3). 739–747. 11 indexed citations
5.
Wen, Zhexu, Yang Zhang, Fangqiu Fu, et al.. (2021). Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules. Journal of Cancer Research and Clinical Oncology. 148(6). 1473–1479. 3 indexed citations
6.
Fu, Fangqiu, Chaoqiang Deng, Zhexu Wen, et al.. (2021). Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational Lung Cancer Research. 10(7). 3144–3154. 19 indexed citations
7.
Fu, Fangqiu, Zhexu Wen, Zhendong Gao, et al.. (2021). Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma. Frontiers in Oncology. 11. 622723–622723. 1 indexed citations
8.
Deng, Chaoqiang, Qiang Zheng, Yang Zhang, et al.. (2021). Validation of the Novel International Association for the Study of Lung Cancer Grading System for Invasive Pulmonary Adenocarcinoma and Association With Common Driver Mutations. Journal of Thoracic Oncology. 16(10). 1684–1693. 78 indexed citations
9.
Zhang, Yang, Fangqiu Fu, Zhendong Gao, et al.. (2021). Subsolid Lesions Exceeding 3 Centimeters: The Ground-Glass Opacity Component Still Matters. The Annals of Thoracic Surgery. 113(3). 984–992. 9 indexed citations
10.
Wen, Zhexu, et al.. (2021). Silencing of miR-483-5p alleviates postmenopausal osteoporosis by targeting SATB2 and PI3K/AKT pathway. Aging. 13(5). 6945–6956. 32 indexed citations
11.
Zhang, Yang, Chaoqiang Deng, Xiao Ma, et al.. (2020). Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy. Journal of Cancer Research and Clinical Oncology. 146(9). 2411–2417. 6 indexed citations
12.
Fu, Fangqiu, Yang Zhang, Zhendong Gao, et al.. (2020). Development and validation of a five‐gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. International Journal of Cancer. 147(2). 584–592. 25 indexed citations
14.
Wen, Zhexu, Yue Zhao, Fangqiu Fu, et al.. (2020). Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter. Journal of Cancer Research and Clinical Oncology. 146(6). 1603–1613. 15 indexed citations
15.
Fu, Fangqiu, Yang Zhang, Zhexu Wen, et al.. (2019). Distinct Prognostic Factors in Patients with Stage I Non–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions. Journal of Thoracic Oncology. 14(12). 2133–2142. 131 indexed citations
16.
Zhang, Yang, Fangqiu Fu, Zhexu Wen, et al.. (2019). Segment Location and Ground Glass Opacity Ratio Reliably Predict Node-Negative Status in Lung Cancer. The Annals of Thoracic Surgery. 109(4). 1061–1068. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026